GlobeNewswire Inc.
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biotechnology company, announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference on November 9-11, 2026 in Boston. The company is advancing its lead clinical program muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody currently in Phase 1b/2 and Phase 2 studies for microsatellite stable metastatic colorectal cancer in combination with anti-PD-1 therapy.